)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Lytix Biopharma
Lytix Biopharma (LYTIX) investor relations material
Lytix Biopharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Feb, 2026
Executive summary
Entered a decisive new phase with strong clinical data, especially for ruxotemitide and LTX-401, and expanded commercialization opportunities.
Interim NeoLIPA study in melanoma showed 44% pathological complete response and 55% major pathological response among first 9 patients, shaping future development and regulatory strategy.
Partnership with Verrica Pharmaceuticals advanced, with promising immune-response data in basal cell carcinoma and preparations for pivotal Phase III trial.
NOK 77.3 million raised in January 2026 via private placement and subsequent offering, strengthening the balance sheet for key milestones.
Leadership and board enhanced to support late-stage execution and commercial readiness.
Financial highlights
Q4 2025 operating expenses were NOK 21.2 million, down from NOK 33 million year-over-year, mainly due to reduced R&D activity.
Cash and short-term investments at Q4 2025 end were NOK 72 million, with NOK 77.3 million raised post-quarter.
Total liabilities at Q4 2025 were NOK 20 million, down from NOK 39 million year-over-year.
Loss for Q4 2025 was NOK 18.7 million, improved from NOK 31.9 million in Q4 2024.
Cash flow from operations was negative NOK 29.5 million in H2 2025, an improvement from negative NOK 33.1 million in H2 2024.
Outlook and guidance
Well-capitalized into mid-2027, supporting clinical and partnering milestones, with focus on pivotal studies and commercialization.
NeoLIPA topline results expected in H2 2026; pivotal study for ruxotemitide in preparation.
LTX-401 clinical entry targeted for 2027, with ongoing evaluation of strategic development opportunities.
Actively pursuing capital raising and pharma partnerships to fund pivotal studies.
Expectation of continued disciplined execution, targeted investment, and strategic collaboration.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lytix Biopharma earnings date
Q1 202621 May, 2026
Lytix Biopharma
Next Lytix Biopharma earnings date
Q1 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Lytix Biopharma is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company specializes in using oncolytic peptides, which are designed to kill cancer cells and stimulate the immune system to generate a strong, systemic T-cell response. This approach aims to overcome the challenges of tumor heterogeneity, where variations in cancer cells within a tumor reduce the effectiveness of conventional immunotherapies. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage